OncoMatch/Clinical Trials/NCT05926063
Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia
Is NCT05926063 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies non-drug interventions for neutropenia, febrile.
The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection is found with the current "golden standard": long-term antibiotic treatment in adult hematology patients who develop neutropenic fever. The main question it aims to answer is: whether the short-term treatment is equally safe for patients, hence the name 'SAFE study'. Participants will be randomly assigned (randomized) to one of two treatment options once they develop neutropenic fever: short-term or long-term antibiotic treatment. An additional blood sample, urine sample and stool sample will be collected. Researchers will compare the short-term and the long-term antibiotic treatment groups to see if the short treatment is equally safe as the long-term treatment group.
Check if I qualifyExtracted eligibility criteria
Demographics
Lab requirements
Blood counts
expected longstanding (≥ 7 days) neutropenia (anc < 0.5x10^9/l)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05926063 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify